JHOP Articles

Skip to main content

Original Research, COVID-19, Adverse Events, Infections

COVID-19 as a Primer for Drug-Induced Pneumonitis in Patients With Cancer

Avani Yenamandra, PharmD, BCOP; Alison Greidinger, MD; Jenia Jenab-Wolcott, MD, PhD

Review Article, Transplant, Adverse Events, Chemotherapy, Methotrexate

Hematopoietic Stem-Cell Transplantation and Drug Considerations in Transgender Patients

Erin Kate Barthelmess, PharmD, BCOP; Sarah Perreault, PharmD, BCPS, BCOP; Ashley Sabus, PharmD, BCOP; Jeffrey E. Topal, MD

FDA Updates

FDA Approved Loqtorzi, a PD-1 Inhibitor, for the Treatment of Adults With Metastatic or Recurrent Nasopharyngeal Carcinoma

FDA Updates

Tibsovo FDA Approved for Patients With Relapsed Myelodysplastic Syndromes and IDH1 Mutation

ESMO Early Breast Cancer

Interview with the Innovators

Evolving Adjuvant Treatment Landscape for HR+/HER2- Early Breast Cancer

Nadia Harbeck, MD, PhD

FDA Updates

Fruzaqla FDA Approved for Refractory Metastatic Colorectal Cancer

FDA Updates

Rozlytrek Now Approved for Pediatric Patients Older Than 1 Month With Solid Tumors and NTRK Gene Fusion and in New Oral Pellet Form

ADC Therapy Treatment HER2+ and HER2-Low mBC

Interview with the Innovators

Educating on HER2-Low mBC

Tajuana Bradley, MS, FNP-BC, Ryan Haumschild, PharmD, MS, MBA, CPEL, Abbey J. Kaler, MS, APRN, FNP-C, Susie Ulloa, RN, OCN, ONN-CG

ADC Therapy Treatment HER2+ and HER2-Low mBC

Interview with the Innovators

Fostering Shared Treatment Decision-Making

Tajuana Bradley, MS, FNP-BC, Ryan Haumschild, PharmD, MS, MBA, CPEL, Abbey J. Kaler, MS, APRN, FNP-C, Susie Ulloa, RN, OCN, ONN-CG

ADC Therapy Treatment HER2+ and HER2-Low mBC

Interview with the Innovators

Setting Appropriate Patient Goals of Therapy

Tajuana Bradley, MS, FNP-BC, Ryan Haumschild, PharmD, MS, MBA, CPEL, Abbey J. Kaler, MS, APRN, FNP-C, Susie Ulloa, RN, OCN, ONN-CG

Page 28 of 197
Results 271 - 280 of 1963